|
预期应用
ELISA法定量测定人血清、血浆或其它相关液体中Lp-PLA2含量。
实验原理
本试剂盒应用双抗体夹心酶标免疫分析法测定标本中Lp-PLA2水平。用纯化的抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入Lp-PLA2抗原、生物素化的抗人Lp-PLA2抗体、HRP标记的亲和素，经过彻底洗涤后用底物TMB显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的Lp-PLA2呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），计算样品浓度。
Intended use
This immunoassay kit allows for the specific measurement of human Lp-PLA2 concentrations in serum and plasma.
Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2, also known as platelet activating factor acetyl-hydrolase), is a relatively recent marker that has emerged as a major, independent predictor of CHD. Lp-PLA2 is an active phospholipase that circulates in plasma bound to LDL, and it appears to act almost exclusively on oxidized LDL to generate lysophosphatidyl-choline, which is proinflammatory and is considered to be atherogenic. Thus, Lp-PLA2 represents an interesting link between lipoproteinoxidation and vascular inflammation, which likely explain its strong, independent association with CHD risk. Data from the recent ARIC study have indicated that the predictive power of Lp-PLA2 is attenuated after adjustment for multiple established risk factors, but remains strong in the sub-group with LDLcholesterol levels of < 130 mg/dL. Moreover, this study indicated that there was an interaction between Lp-PLA2 and CRP levels, and the strongest predictor for CHD risk (hazard ratio = 2.95) was found for the combination of high CRP (> 3 mg/L) and high Lp-PLA2 (= 422 µg/L) in the presence of LDL < 130 mg/dL. Therefore, CRP and Lp- PLA2 appear to be particularly useful in predicting CHD risk in the presence of LDL cholesterol in the normal range. |
